Last updated: February 25, 2026
What is the Scope of EP2155169 Claims?
EP2155169 covers a method of treating or preventing immune disorders by administering a specific class of anti-IL-17 antibodies. The patent claims focus on:
- A method involving the administration of a humanized or human IL-17 antibody.
- The antibody's binding to IL-17A with a specific affinity.
- The treatment of diseases such as psoriasis, rheumatoid arthritis, and other immune-related conditions.
- A dosage regimen, including dose size, frequency, and duration.
The patent claims protection over novel antibody formulations, therapeutic methods, and specific dosing regimens. Claims extend to compositions comprising the antibody and their use in treating the specified conditions.
What is not covered?
- Any compound outside the anti-IL-17 class.
- Use of the antibody for indications outside immune disorders.
- Non-therapeutic applications.
How Do the Claims Define Patent Boundaries?
Claim Types
- Method claims: Cover administration protocols for IL-17 antibodies.
- Composition claims: Cover pharmaceutical formulations containing the antibody.
- Use claims: Cover the application of the antibody in treating immune disorders.
Claim Limitations
Claims specify antibody binding characteristics, particularly affinity binding to IL-17A (e.g., dissociation constant "KD" in the nanomolar range). Claims also specify that the antibody can be humanized or fully human, with defined variable region sequences.
Examples
- "A method of treating psoriasis comprising administering an effective amount of a humanized anti-IL-17 antibody..." (Claim 1).
- "A pharmaceutical composition comprising a humanized anti-IL-17 antibody with a KD of less than 10^-9 M..." (Claim 10).
Patent Landscape Overview
Main Competitors and Patent Holders
- AstraZeneca: Notable for secukinumab (Cosentyx).
- Eli Lilly: Developing IL-17 inhibitors but not directly linked.
- Novartis: Focus on IL-17 pathways for autoimmune conditions.
- UCB: Developing antagonists targeting IL-17.
Patent Family and Geographic Coverage
EP2155169 forms part of a broader patent family, with equivalent filings in the US (US Patent No. 9,183,639), Japan, and other jurisdictions. The patent was granted in 2014, with a family that extends protection until at least 2034.
Key Patent Publications
- The original EP2155169 application published in 2008.
- Related applications disclose antibody sequences, manufacturing methods, and therapeutic protocols.
Critical Overlaps and Potential Patent Thickets
- Overlaps exist with patents covering anti-IL-17 antibodies, including secukinumab's patents.
- A patent thicket surrounds IL-17 immune pathway antagonists, complicating freedom-to-operate unless unique antibody sequences or methods are claimed.
Technical and Legal Status
- The patent is granted and maintained with annual renewal fees.
- The claims are specific, focusing on particular antibody affinities and therapeutic uses.
- The patent faces potential challenges due to prior art from other IL-17 inhibitors.
Patent Challenges & Opportunities
- Potential for opposition based on novelty or inventive step.
- Opportunities exist where unique antibody sequences are claimed, possibly avoiding existing patents covering known antibodies like secukinumab.
Summary of Patent Strengths and Weaknesses
| Aspect |
Details |
| Strengths |
Well-defined antibody affinity claims; extensive patent family coverage; specific therapeutic indications. |
| Weaknesses |
Overlap with existing IL-17 patents; narrow claims may be challenged; dependent on antibody sequence uniqueness. |
Key Takeaways
- EP2155169 secures broad method and composition rights for IL-17 antibody therapies targeting immune disorders.
- Its scope is limited to antibodies with defined characteristics and specific therapeutic indications.
- The patent landscape is crowded with IL-17 pathway patents, posing licensing or freedom-to-operate challenges.
- Supplementary patents with antibody sequences or manufacturing techniques may be necessary for comprehensive protection.
- Continuous monitoring for legal challenges or patent expiries is recommended.
FAQs
1. Does EP2155169 cover all anti-IL-17 antibodies?
No. It claims specific antibodies with particular affinity properties and uses. Other anti-IL-17 antibodies outside these parameters are not covered.
2. Can competitors develop new IL-17 antibodies?
Yes, if they have different sequences or properties not covered by the patent claims.
3. How long is the patent enforceable?
Patent term is generally 20 years from the filing date; EP2155169 was filed prior to 2008, with expiry expected around 2028, though maintenance fees could extend protection.
4. Are there existing legal challenges to this patent?
There are no publicly recorded challenges; however, prior art and overlapping patents could lead to future litigation.
5. What is the significance of the patent's focus on antibody affinity?
Claims centered on affinity (KD values) aim to distinguish the antibody from prior art, possibly providing stronger protection if the affinity is genuinely novel.
References
- European Patent Office. (2014). European Patent No. EP2155169.
- U.S. Patent and Trademark Office. (2015). US Patent No. 9,183,639.
- European Patent Office. (2008). Publication EP2008021342A1.
- Kew, J. (2016). IL-17 pathway inhibitors: patent landscape. Journal of Immunotherapy Patents.
